Apricus
Biosciences, Inc. APRI
and Stellar Pharmaceuticals Inc. SLXCF
SLXCF (Pink Sheets:SLXCF), a Canadian public company, announced today
the signing of an exclusive license agreement. Under the agreement, Stellar
Pharma has the exclusive right to sell Apricus Bio's MycoVa™ product for the
treatment of onychomycosis (nail fungus) in Canada, following receipt of
Canadian regulatory approval for such product. The exclusive license agreement
provides for an upfront payment, regulatory approval milestone, sales
achievement milestones and royalty payments during the term of the agreement.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in